Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer
Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection is the only potentially curative resection. The results of adjuvant treatment either with chemotherapy or with radiotherapy have been contradictory and the incidence of local-regional recurrence remai...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/506571 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562416799449088 |
|---|---|
| author | Antonios-Apostolos K. Tentes Dimitrios Kyziridis Stylianos Kakolyris Nicolaos Pallas Georgios Zorbas Odysseas Korakianitis Christos Mavroudis Nicolaos Courcoutsakis Panos Prasopoulos |
| author_facet | Antonios-Apostolos K. Tentes Dimitrios Kyziridis Stylianos Kakolyris Nicolaos Pallas Georgios Zorbas Odysseas Korakianitis Christos Mavroudis Nicolaos Courcoutsakis Panos Prasopoulos |
| author_sort | Antonios-Apostolos K. Tentes |
| collection | DOAJ |
| description | Background and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection is the only potentially curative resection. The results of adjuvant treatment either with chemotherapy or with radiotherapy have been contradictory and the incidence of local-regional recurrence remains high. If local-regional recurrence is controlled survival may be expected to increase. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) may be used in order to control local-regional recurrences. The purpose of the study is to identify the effect of HIPEC in patients with pancreatic cancer undergoing potentially resection.
Patients and Methods. From 2007–2011, 21 patients, mean age 69.4±9.5 (50–86) years, underwent tumor resection, and HIPEC with gemcitabine. The hospital mortality and morbidity rate was 9.5% and 33.3%, respectively. 5-year and median survival was 23% and 11 months, respectively. The recurrence rate was 50% but no patient developed local-regional recurrence. No patient was recorded with gemcitabine-induced toxicity. Conclusions. This clinical study of 21 patients is the first to combine an R0 pancreas cancer resection with HIPEC. Increased morbidity and mortality from intraoperative gemcitabine was not apparent. Patients with pancreatic cancer undergoing potentially curative resection in combination with HIPEC may be offered a survival benefit. Data suggested that local-regional recurrences may be greatly reduced. Further studies with greater number of patients are required to confirm these findings. |
| format | Article |
| id | doaj-art-8a67600de97e4ca99ec5968ef980caff |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-8a67600de97e4ca99ec5968ef980caff2025-02-03T01:22:38ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/506571506571Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic CancerAntonios-Apostolos K. Tentes0Dimitrios Kyziridis1Stylianos Kakolyris2Nicolaos Pallas3Georgios Zorbas4Odysseas Korakianitis5Christos Mavroudis6Nicolaos Courcoutsakis7Panos Prasopoulos8Surgical Department, Didimotichon General Hospital, Didimotichon 68300, GreeceSurgical Department, Didimotichon General Hospital, Didimotichon 68300, GreeceDepartment of Clinical Oncology, Alexandroupolis General Hospital, Democritus University of Thrace, GreeceSurgical Department, Didimotichon General Hospital, Didimotichon 68300, GreeceSurgical Department, Didimotichon General Hospital, Didimotichon 68300, GreeceDepartment of Anesthesiology, Didimotichon General Hospital, GreeceSurgical Department, Didimotichon General Hospital, Didimotichon 68300, GreeceDepartment of Radiology, Alexandroupolis General Hospital, Democritus University of Thrace, GreeceDepartment of Radiology, Alexandroupolis General Hospital, Democritus University of Thrace, GreeceBackground and Aims. 5-year survival in patients with pancreatic cancer is poor. Surgical resection is the only potentially curative resection. The results of adjuvant treatment either with chemotherapy or with radiotherapy have been contradictory and the incidence of local-regional recurrence remains high. If local-regional recurrence is controlled survival may be expected to increase. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) may be used in order to control local-regional recurrences. The purpose of the study is to identify the effect of HIPEC in patients with pancreatic cancer undergoing potentially resection. Patients and Methods. From 2007–2011, 21 patients, mean age 69.4±9.5 (50–86) years, underwent tumor resection, and HIPEC with gemcitabine. The hospital mortality and morbidity rate was 9.5% and 33.3%, respectively. 5-year and median survival was 23% and 11 months, respectively. The recurrence rate was 50% but no patient developed local-regional recurrence. No patient was recorded with gemcitabine-induced toxicity. Conclusions. This clinical study of 21 patients is the first to combine an R0 pancreas cancer resection with HIPEC. Increased morbidity and mortality from intraoperative gemcitabine was not apparent. Patients with pancreatic cancer undergoing potentially curative resection in combination with HIPEC may be offered a survival benefit. Data suggested that local-regional recurrences may be greatly reduced. Further studies with greater number of patients are required to confirm these findings.http://dx.doi.org/10.1155/2012/506571 |
| spellingShingle | Antonios-Apostolos K. Tentes Dimitrios Kyziridis Stylianos Kakolyris Nicolaos Pallas Georgios Zorbas Odysseas Korakianitis Christos Mavroudis Nicolaos Courcoutsakis Panos Prasopoulos Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer Gastroenterology Research and Practice |
| title | Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer |
| title_full | Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer |
| title_fullStr | Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer |
| title_full_unstemmed | Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer |
| title_short | Preliminary Results of Hyperthermic Intraperitoneal Intraoperative Chemotherapy as an Adjuvant in Resectable Pancreatic Cancer |
| title_sort | preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer |
| url | http://dx.doi.org/10.1155/2012/506571 |
| work_keys_str_mv | AT antoniosapostolosktentes preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT dimitrioskyziridis preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT stylianoskakolyris preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT nicolaospallas preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT georgioszorbas preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT odysseaskorakianitis preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT christosmavroudis preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT nicolaoscourcoutsakis preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer AT panosprasopoulos preliminaryresultsofhyperthermicintraperitonealintraoperativechemotherapyasanadjuvantinresectablepancreaticcancer |